Barclays
RYTM icon

Barclays’s Rhythm Pharmaceuticals RYTM Stock Holding History

Barclays’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,600
Closed -$230K – 5447
2024
Q2 		$230K Hold
5,600
– – ﹤0.01% 3506
2024
Q1 		$243K Hold
5,600
– – ﹤0.01% 4009
2023
Q4 		$257K Buy
+5,600
New +$177K ﹤0.01% 4307

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Barclays's RYTM Position: Q2 2026 in Review

Barclays increased its Rhythm Pharmaceuticals (RYTM) stake by 24% in Q2 2026, buying an estimated $231K and bringing the position to 13,209 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Barclays first reported a position in RYTM in Q4 2017 and has held it in 35 quarters since. The position peaked at $22.2M in Q2 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Barclays held 13,209 shares of Rhythm Pharmaceuticals worth $1.47M as of Q2 2026.
  • Barclays bought 2,557 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $231K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2549 holding.
  • Barclays first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
  • Barclays's Rhythm Pharmaceuticals position peaked at $22.2M in Q2 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.